Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more
Redhill Biopharma Ltd (RDHL) - Total Liabilities
Latest total liabilities as of June 2025: $22.79 Million USD
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has total liabilities worth $22.79 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Redhill Biopharma Ltd - Total Liabilities Trend (2010–2024)
This chart illustrates how Redhill Biopharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Redhill Biopharma Ltd Competitors by Total Liabilities
The table below lists competitors of Redhill Biopharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cathay Pacific Airways Limited
BE:CTY
|
Germany | €114.08 Billion |
|
Chai Communication Co.,LTD.
KQ:351870
|
Korea | ₩99.36 Billion |
|
Arinsiri Land Public Company Limited
BK:ARIN
|
Thailand | ฿491.97 Million |
|
Issta Lines Ltd
TA:ISTA
|
Israel | ILA2.29 Billion |
|
Sin Heng Heavy Machinery Ltd
F:SNVA
|
Germany | €18.35 Million |
|
LANCOR HOLDINGS LTD.
NSE:LANCORHOL
|
India | ₹2.37 Billion |
|
Tsodilo Resources Limited
OTCQB:TSDRF
|
USA | $4.41 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Redhill Biopharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.56 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -5.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Redhill Biopharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Redhill Biopharma Ltd (2010–2024)
The table below shows the annual total liabilities of Redhill Biopharma Ltd from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $22.73 Million | +8.33% |
| 2023-12-31 | $20.98 Million | -89.88% |
| 2022-12-31 | $207.27 Million | +20.29% |
| 2021-12-31 | $172.31 Million | +3.57% |
| 2020-12-31 | $166.38 Million | +1080.23% |
| 2019-12-31 | $14.10 Million | +25.59% |
| 2018-12-31 | $11.22 Million | -8.58% |
| 2017-12-31 | $12.28 Million | +6.66% |
| 2016-12-31 | $11.51 Million | +70.51% |
| 2015-12-31 | $6.75 Million | +75.58% |
| 2014-12-31 | $3.85 Million | +59.21% |
| 2013-12-31 | $2.42 Million | +124.03% |
| 2012-12-31 | $1.08 Million | -22.94% |
| 2011-12-31 | $1.40 Million | -88.44% |
| 2010-12-31 | $12.10 Million | -- |